tiprankstipranks
Advertisement
Advertisement

TARA Stock Latest News

Protara Therapeutics Stockholders Approve Governance and Share Increases
Company AnnouncementsProtara Therapeutics Stockholders Approve Governance and Share Increases
6d ago
8K
TARA
Protara Therapeutics price target raised to $28 from $25 at Oppenheimer
PremiumThe Fly
Protara Therapeutics price target raised to $28 from $25 at Oppenheimer
1M ago
TARA
Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential
PremiumRatings
Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential
1M ago
TARA
Unusually active option classes on open May 15th
PremiumThe Fly
Unusually active option classes on open May 15th
1M ago
AGQ
CSX
Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial
PremiumThe Fly
Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial
1M ago
TARA
Protara Therapeutics price target lowered to $26 from $27 at JPMorgan
PremiumThe FlyProtara Therapeutics price target lowered to $26 from $27 at JPMorgan
1M ago
TARA
Protara Therapeutics files $300M mixed securities shelf
Premium
The Fly
Protara Therapeutics files $300M mixed securities shelf
1M ago
TARA
Protara Therapeutics reports Q1 EPS (31c), consensus (37c)
Premium
The Fly
Protara Therapeutics reports Q1 EPS (31c), consensus (37c)
1M ago
TARA
JPMorgan healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
JPMorgan healthcare analysts hold an analyst/industry conference call
2M ago
CGON
TARA
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
PremiumCompany Announcements
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
3M ago
8K
TARA
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
PremiumRatings
Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway
3M ago
TARA
Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028
PremiumRatings
Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028
3M ago
TARA
Protara Therapeutics reports Q4 EPS (37c), consensus (31c)
PremiumThe FlyProtara Therapeutics reports Q4 EPS (37c), consensus (31c)
3M ago
TARA
Protara Therapeutics sees cash runway into 2028
Premium
The Fly
Protara Therapeutics sees cash runway into 2028
3M ago
TARA
TARA Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
TARA Upcoming Earnings Report: What to Expect?
3M ago
TARA
De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara
PremiumRatings
De-Risked Lead Asset and Underappreciated Pipeline Upside Support Buy Rating on Protara
4M ago
TARA
Protara Therapeutics initiated with an Overweight at JPMorgan
PremiumThe Fly
Protara Therapeutics initiated with an Overweight at JPMorgan
4M ago
TARA
Protara Highlights Strong Phase 2 Data for TARA-002
PremiumCompany Announcements
Protara Highlights Strong Phase 2 Data for TARA-002
4M ago
8K
TARA
Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC
PremiumRatings
Reframing TARA‑002’s Potential: Underappreciated Durability and Commercial Upside in BCG‑Unresponsive NMIBC
4M ago
TARA
Buy Rating on TARA-002 Supported by Comparable Efficacy and $500M Peak Sales Opportunity in Bladder Cancer
PremiumRatingsBuy Rating on TARA-002 Supported by Comparable Efficacy and $500M Peak Sales Opportunity in Bladder Cancer
4M ago
TARA
Protara Therapeutics says TARA-002 demonstrates 68% CR rate at 6 months
Premium
The Fly
Protara Therapeutics says TARA-002 demonstrates 68% CR rate at 6 months
4M ago
TARA
Protara Therapeutics management to meet with Oppenheimer
Premium
The Fly
Protara Therapeutics management to meet with Oppenheimer
5M ago
TARA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >